MX2020008387A - Usos terapeuticos de agonistas glp1r. - Google Patents

Usos terapeuticos de agonistas glp1r.

Info

Publication number
MX2020008387A
MX2020008387A MX2020008387A MX2020008387A MX2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A
Authority
MX
Mexico
Prior art keywords
glp1r
certain
aspects
disclosure provides
agonists
Prior art date
Application number
MX2020008387A
Other languages
English (en)
Inventor
Jennifer L R Freeman
Lopez Maria Carmen Valcarce
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2020008387A publication Critical patent/MX2020008387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los métodos para usar agonistas de receptor de péptido 1 similar al glucagón (GLP1R) se describen en general en la presente. En ciertos aspectos, la descripción proporciona métodos para tratar diabetes tipo 2 que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para tratar obesidad que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para disminuir hemoglobina glicada (por ejemplo, disminuir HbAlc} que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. Las composiciones que contienen agonistas GLP1R y su manufactura, por ejemplo, para uso como un medicamento también se describen en la presente.
MX2020008387A 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r. MX2020008387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Publications (1)

Publication Number Publication Date
MX2020008387A true MX2020008387A (es) 2020-12-11

Family

ID=66484210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008387A MX2020008387A (es) 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r.

Country Status (10)

Country Link
US (1) US20210023072A1 (es)
EP (1) EP3790549A1 (es)
JP (2) JP2021523877A (es)
KR (1) KR20210005843A (es)
AU (1) AU2019266114A1 (es)
CA (1) CA3090823A1 (es)
MX (1) MX2020008387A (es)
SG (1) SG11202007966UA (es)
TW (1) TW202015683A (es)
WO (1) WO2019217165A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702404B2 (en) 2019-10-25 2023-07-18 Gilead Sciences, Inc. GLP-1R modulating compounds
US20230174546A1 (en) * 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of glp-1 receptor agonist and preparation method therefor
US20230174547A1 (en) * 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor
EP4159722A4 (en) * 2020-05-28 2024-06-26 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST
US20230382921A1 (en) * 2020-09-21 2023-11-30 Vtv Therapeutics Llc Amorphous Form of Isoquinoline Derivative
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
CR20230495A (es) 2021-04-21 2023-11-30 Gilead Sciences Inc Compuestos moduladores del glp-ir carboxibenzimidazólicos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
BRPI0910282A2 (pt) 2008-03-07 2015-09-01 Transtech Pharma Inc Composto oxadiazo-antraceno para o tratamento de diabetes
AU2010232750B2 (en) 2009-03-30 2015-10-29 Vtv Therapeutics Llc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
SG11201405353VA (en) * 2012-03-22 2014-09-26 Transtech Pharma Llc Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
ES2687083T3 (es) * 2013-01-17 2018-10-23 Vtv Therapeutics Llc Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos

Also Published As

Publication number Publication date
KR20210005843A (ko) 2021-01-15
SG11202007966UA (en) 2020-11-27
JP2021523877A (ja) 2021-09-09
US20210023072A1 (en) 2021-01-28
WO2019217165A1 (en) 2019-11-14
CA3090823A1 (en) 2019-11-14
AU2019266114A1 (en) 2020-08-27
EP3790549A1 (en) 2021-03-17
TW202015683A (zh) 2020-05-01
JP2024112903A (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
NZ732000A (en) Gip and glp-1 co-agonist compounds
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
PH12017500761A1 (en) Co-agonists of glucagon and glp-1 receptors
MX2023001980A (es) Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo.
TN2015000053A1 (en) Fusion proteins for treating a metabolic syndrome
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
EP3575314A3 (en) Glucagon derivatives
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
MX2021015154A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
AU2019284019A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
PH12020500338A1 (en) Acylated oxyntomodulin peptide analog
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2022011089A (es) Peptidos como agonistas selectivos del receptor de gip.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2024000757A (es) Variantes recombinantes de proteínas r-espondina y uso de las mismas.
WO2014193832A3 (en) Glucagon-like peptide 1 (glp-1) receptor modulators and uses thereof in regulating blood glucose levels
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
MX2021012177A (es) Usos terapeuticos de dulaglutida.
MX2024004398A (es) Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
MX2022006599A (es) Terapia de combinacion usando co-agonistas de glucagon y glp-1 para el tratamiento de la obesidad.